In 2009, Dr. Hua used the mild SMA models of Taiwanese mice to construct a severe SMA model that was more suitable for drug screening (50% SMA mice per litter, with an average lifespan of 10 days) and developed a monoclonal antibody that could specifically recognize human SMN protein which laid the foundation for animal experiments (Hua et al., 2010, 2011). This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.